ClinicalTrials.gg
CompletedNCT02447666Updated Jul 11, 2019

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

A Phase 2 interventional study of Azacitidine in Myelodysplastic Syndrome and Leukemia, Myelomonocytic, Juvenile, sponsored by Celgene. Completed at 39 sites in 13 countries. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2019-07-11.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
1 Month to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
80th of 126
28 · median 38
Started
2015
with 8 others
Phase 2
63 of 130
5 open now
Registered
78th of 130
by date
Lead sponsor
14 of 130
Celgene

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 80th largest by enrollment of the 126 interventional ones that give a count, is one of 9 that started in 2015, is one of 63 in phase 2, and was the 78th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 1 Month to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

Indication Treatment of pediatric subjects with newly diagnosed advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) prior to hematopoietic stem cell transplantation (HSCT).

Objectives Primary Objective The primary objective is to assess the treatment effect on response rate (MDS: either complete remission [CR], partial remission [PR], or marrow CR; JMML: either clinical complete remission [cCR] or clinical partial remission [cPR]); at Cycle 3 Day 28 (each cycle is 28 days) and to compare against standard therapy using a matched-pairs analysis of historical data.

Secondary Objective The secondary objective is to further evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of azacitidine in this subject population.

Study Design This is a prospective, open-label, Phase 2 study consisting of 2 parallel experimental arms, one for each disease group: MDS and JMML. Each arm is designed based on Simon's Optimal 2 stage study design. The sample size has been calculated to allow evaluation of the response rate at 28 day-Cycle 3 Day 28 in each of the 2 disease groups. Each of the experimental arms will also individually be compared against a historical control arm using data retrospectively collected from the European Working Group of MDS in childhood (EWOG-MDS) registry by means of a matched-pairs analysis; matched for predefined subject baseline characteristics defined before any results from this study are known post Stage 1. If matched pair is not viable then other methodologies will be explored to evaluate and compare response rates reported in literature and also in registry database Twenty subjects with MDS and 35 JMML subjects evaluable for the primary endpoint (ie, subjects that receive at least 1 dose of investigational product [IP]) will be enrolled at approximately 45 centers in Europe. Each experimental arm has 1 interim analysis planned (at the end of Stage 1). If, during Stage 1 evaluation, less than 2 subjects are observed with a CR, PR, or marrow CR after 3 months of azacitidine in the first 9 subjects with MDS, then enrollment will be stopped. Similarly, if less than 3 subjects are observed with a cPR or cCR after 3 months of azacitidine in the first 18 subjects with JMML, then enrollment will be stopped.

Read the detailed description

Study Population Pediatric subjects aged 1 month to less than 18 years of age with newly diagnosed conditions of advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML).

Length of Study The enrollment period will last for up to 22 months with subjects being treated for a minimum of 3 months and a maximum of 6 months, until transplantation or disease progression (based on an independent central review of responses). Once investigational product (IP) has been discontinued, subjects will then be followed for 1 year after the last dose of investigational product (IP). The follow-up may not be terminated because of new anticancer treatment or hematopoietic stem cell transplantation (HSCT).

The End of Trial is defined as either the date of the last visit of the last subject to complete the study, or the date of receipt of the last data point from the last subject that is required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol and/or the Statistical Analysis Plan (SAP), whichever is the later date.

03

Conditions studied

  • Myelodysplastic Syndrome
  • Leukemia, Myelomonocytic, Juvenile

Keywords

  • Azacitidine
  • Myelodysplastic syndrome
  • Juvenile myelomonocytic leukemia
  • Hematopoietic stem cell transplantation
  • Vidaza
  • Hypomethylating agent
04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Myelodysplastic Syndromes (MDS) :

  1. Understand and voluntarily provide permission (subjects and/or when applicable, parental/legal representative) to the form/informed assent form (ICF/IAF) prior to conducting any study-related assessments/procedures.
  2. Able to adhere to the study visit schedule and other protocol requirements.
  3. Male or female age 1 month to less than 18 years old at the time of informed consent/informed assent.
  4. Newly diagnosed advanced primary or secondary Myelodysplastic Syndromes (MDS), with latest peripheral blood (PB) and bone marrow (BM) confirming diagnosis within the 14 days prior to informed consent signature, with one of the following:

    1. RAEB ( anemia with excess blasts): 2% to 19% blasts in PB or 5% to 19% blasts in BM.
    2. RAEB-t (Refractory anemia with excess blasts in transformation): 20% to 29% of blasts in PB or BM.
    3. Secondary Myelodysplastic Syndromes presenting as chronic myelomonocytic leukemia (CMML) without increase in blasts but with chromosomal abnormality
  5. Lansky play score at least equal to 60; or performance status at least equal to 60.
  6. of at least 3 months.
  7. Normal renal function defined as less than or equal to (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]) v 4.0 Grade 1 (maximum 1.5 x [ULN]).
  8. Normal liver function defined as less than or equal to NCI CTCAE v 4.0 Grade 1 (maximum 2.5 x ULN for transaminases and ).
  9. Females of and male subjects that have reached puberty and are younger than 18 years of age must agree to undergo physician-approved reproductive education and discuss the side effects of the Product (IP) on reproduction with parent(s) and/or guardian(s).
  10. Females of childbearing potential, defined as females who have achieved menarche and/or 8 years or older and have not undergone a hysterectomy or bilateral oophorectomy, must meet the following conditions below. (Note: Amenorrhea following cancer therapy does not rule out childbearing potential):

    1. Have a negative serum pregnancy test within 72 hours prior to starting IP as verified by the Investigator. Agree to ongoing pregnancy testing during the course of the study
    2. Female subjects must, as appropriate to age and the discretion of the study physician, either commit to true abstinence1 from heterosexual contact (which must be reviewed on a monthly basis) and/or agree to the use of approved method (eg. oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; or vasectomized partner) while on azacitidine; and for 3 months following the last dose.
  11. Male subjects must, as appropriate to age and the discretion of the study physician:

    1. Agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential (FCBP) while participating in the study, during dose interruptions, and for at least 3 months following azacitidine discontinuation, even if he has undergone a successful vasectomy.

Juvenile Myelomonocytic Leukemia Subjects (JMML):

  1. Understand and voluntarily provide permission (subjects and/or when applicable, parental/legal representative) to the ICF/IAF prior to conducting any study-related assessments/procedures.
  2. Able to adhere to the study visit schedule and other protocol requirements.
  3. Male or female age 1 month to less than 18 years old at the time of informed consent/informed assent.
  4. Newly diagnosed Juvenile Myelomonocytic Leukemia (JMML), with PB and BM confirming diagnosis prior to informed consent signature, with one of the following

    1. somatic mutation in PTPN11
    2. somatic mutation in KRAS
    3. somatic mutation in NRAS and HbF % > 5x normal value for age
    4. clinical diagnosis of neurofibromatosis Type 1.
  5. Lansky play score at least equal to 60; or Karnofsky performance status at least equal to 60.
  6. Life expectancy of at least 3 months.
  7. Normal renal function defined as less than or equal to NCI CTCAE v 4.0 Grade 1 (maximum 1.5 x ULN).
  8. Normal liver function defined as less than or equal to NCI CTCAE v 4.0 Grade 1 (maximum 2.5 x ULN for transaminases and bilirubin).
  9. Females of childbearing potential and male subjects that have reached puberty and are younger than 18 years of age must agree to undergo physician-approved reproductive education and discuss the side effects of the IP on reproduction with parent(s) and/or guardian(s).
  10. Females of childbearing potential, defined as females who have achieved menarche and/or 8 years or older and have not undergone a hysterectomy or bilateral oophorectomy, must meet the following conditions below.

    1. Have a negative serum pregnancy test within 72 hours prior to starting IP as verified by the Investigator. Agree to ongoing pregnancy testing during the course of the study
    2. Female subjects must, as appropriate to age and the discretion of the study physician, either commit to true abstinence2 from heterosexual contact (which must be reviewed on a monthly basis) and/or agree to the use of approved contraceptive method (eg. oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; or vasectomized partner) while on azacitidine; and for 3 months following the last dose.
  11. Male subjects must, as appropriate to age and the discretion of the study physician:

    a. Agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential (FCBP) while participating in the study, during dose interruptions, and for at least 3 months following azacitidine discontinuation, even if he has undergone a successful vasectomy.

  12. SO2 greater than 92% (without additional supply of O2).
  13. Peripheral blood monocyte count of at least 1.0 x 109/L.
  14. Blast percentage in PB and BM less than 20%.
  15. Splenomegaly.

Exclusion criteria

Exclusion Criteria:

Myelodysplastic Syndromes (MDS):

  1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Any condition that confounds the ability to interpret data from the study.
  4. Treated by any agent in a clinical study within 4 weeks prior to signing of / informed assent.
  5. Any central nervous system (CNS) involvement.
  6. Isolated extramedullary disease.
  7. Current uncontrolled infection.
  8. Cardiac toxicity (shortening fraction below 28%).
  9. Concurrent treatment with another anticancer therapy.
  10. Pregnancy or lactation.
  11. Prior treatment with a demethylating agent.
  12. Allergy to azacitidine or mannitol.
  13. Any other organ dysfunction ( v 4.0 Grade 4) that will interfere with the administration of the therapy according to this protocol.
  14. Genetic abnormalities indicative of Core Binding factor AML; t(8;21), inv16, t(16;16), and t(15;17).
  15. Subjects with inherited BM failure syndromes (ie, Fanconi's anemia, congenital severe neutropenia, Shwachman-Diamond syndrome).

Juvenile Myelomonocytic Leukemia Subjects:

  1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Any condition that confounds the ability to interpret data from the study.
  4. Treated by any investigational agent in a clinical study within 4 weeks prior to signing of informed consent / informed assent.
  5. Any CNS involvement.
  6. Isolated extramedullary disease.
  7. Current uncontrolled infection.
  8. Cardiac toxicity (shortening fraction below 28%).
  9. Concurrent treatment with another anticancer therapy.
  10. Pregnancy or lactation.
  11. Prior treatment with a demethylating agent.
  12. Allergy to azacitidine or mannitol.
  13. Any other organ dysfunction (NCI-CTCAE v 4.0 Grade 4) that will interfere with the administration of the therapy according to this protocol.
  14. Germline molecular aberrations in CBL, PTPN11, NRAS, or KRAS.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Azacitidine Myelodysplastic Syndrome (MDS)

    Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.

    Drug: Azacitidine

  • Experimental
    Azacitidine Juvenile Myelomonocytic Leukemia (JMML)

    Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.

    Drug: Azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Myelodysplastic Syndrome (MDS) response rate at end of third 28-day cycle

    Defined as proportion of subjects with complete remission \[CR\], partial remission \[PR\] or marrow CR according to modified criteria described by Cheson 2006, adapted to pediatric reference values at 3 months (28 days cycle). Response must be sustained for at least 4 weeks either in the 4-week period preceding or succeeding 3 months (ie, sustained over the period minimum 2 months to end of 3 months, or end of 3 months to end of 4th months).

    Time frame: Up to 4 Months

  2. Juvenile Myelomonocytic Leukemia (JMML) response rate at end of 3 Months

    Defined as proportion of subjects with sustained clinical complete remission \[cCR\] or clinical partial remission \[cPR\] according to the International JMML response criteria in Niemeyer 2014 at 3 months (28 days cycles). Response must be sustained for at least 4 weeks either in the 4-week period preceding or succeeding 3 months (ie, sustained over the period minimum 2 months to end of 3 months, or end of 3 monthsto end of 4 months).

    Time frame: Up to 4 Months

Secondary outcomes

  1. Cytogenetic response for MDS

    Cytogenetic response is defined as the number of subjects with complete disappearance of the chromosomal abnormality without appearance of new ones divided by the number of subjects within the analysis population.

    Time frame: Up to 6 Months

  2. Cytogenetic response for JMML subjects

    Cytogenetic response is defined as the number of subjects with complete disappearance of the chromosomal abnormality without appearance of new ones divided by the number of subjects within the analysis population.

    Time frame: Up to 6 Months

  3. Molecular Response for JMML subjects

    Molecular response is defined as the number of subjects with absence of somatic mutations related to JMML divided by the number of subjects within the analysis population.

    Time frame: Up to 6 Months

  4. Duration of Response (CR, PR or marrow CR) for MDS patients

    Duration of response will consist of only the subjects achieving a response (CR, PR or marrow CR) and is defined as the time from first observed response until either disease progression or any cause of death.

    Time frame: Up to 30 months

  5. Duration of Response (Clinical CR or Clinical PR) for JMML patients

    Duration of response will consist of only the subjects achieving a response (cCR or cPR) and is defined as the time from first observed response until either disease progression or any cause of death.

    Time frame: Up to 18 months

  6. Time to Response (TTR) for MDS patients

    TTR is defined as the time from first study dose day until a response of CR, PR or marrow CR, whichever occurs first. Only subjects observed with a response will be included in the analysis with the median TTR across the subjects presented.

    Time frame: Up to 6 Months

  7. TTR of Clinical CR or Clinical PR for JMML patients

    Time to Response (TTR) is defined as the time from first study dose day until a response cCR or cPR, whichever occurs first. Only subjects observed with a response will be included in the analysis with the median TTR across the subjects presented.

    Time frame: Up to 6 Months

  8. Time to Progression (TTP)

    Time to Progression (TTP) is defined as the time from first study dose day until either disease progression or death due to progression.

    Time frame: Up to 18 months

  9. Leukemia free survival (LFS)

    Leukemia free survival (LFS) is defined as the time from HEMATOPOIETIC STEM CELL transplant (HSCT) date until leukemia progression or death for subjects receiving a HSCT only. Subjects alive and leukemia-free at the time of the statistical analysis will be censored at the time of their last disease assessment. Subjects will also be censored at the time of starting a new anticancer therapy if having not previously had a leukemia progression.

    Time frame: Up to 18 months

  10. Overall survival (OS)

    OS is defined as the time from first study dose day until death from any cause. Subjects alive at the time of analysis will be censored at the time they were last known to be alive.

    Time frame: Up to 18 months

  11. Deoxyribonucleic acid methylation status in (BM)

    DNA methylation levels will be assessed across time points by means of a repeated measures analysis of variance (ANOVA) test thereby allowing identification of possible changes in methylation levels over time by treatment arm as well as comparing DNA methylation levels between treatment arms per disease indication

    Time frame: Up to 18 months

  12. Percentage of subjects undergoing HSCT

    Defined as the proportion of subjects undergoing HSCT during the conduct of this study over the total number of subjects enrolled into this study.

    Time frame: Up to 18 months

  13. Time to first HSCT

    The time from first study dose day until HSCT date. Subjects not receiving a HSCT will be censored at the time of the analysis.

    Time frame: Up to 18 months

  14. Adverse Events (AEs)

    All reported adverse events during the duration of the study conduct.

    Time frame: Up to 7 months

  15. Pharmacokinetic parameters of azacitidine; Cmax

    Cmax is defined as the observed maximum plasma concentration

    Time frame: Up to 28 days

  16. Pharmacokinetic parameters of azacitidine; Tmax

    Tmax is defined as the observed time to maximum plasma concentration

    Time frame: Up to 28 days

  17. Pharmacokinetic parameters of azacitidine; AUCt

    Area under the plasma concentration-time curve from time zero to the last quantifiable time point

    Time frame: Up to 28 days

  18. Pharmacokinetic parameters of azacitidine; area under the plasma concentration-time curve from time zero to infinity (AUC ∞)

    The AUC ∞ is defined as area under the plasma concentration-time curve from time zero to infinity

    Time frame: Up to 28 days

  19. Pharmacokinetic parameters of azacitidine; Terminal Rate λz

    Terminal phase rate constant is determined by linear regression of the terminal points of the log-linear plasma concentration-time curve

    Time frame: Up to 28 days

  20. Pharmacokinetic parameters of azacitidine; terminal phase half-life

    The Terminal phase half-life will be calculated according to the following equation: t½ = 0.693/λz

    Time frame: Up to 28 days

  21. Pharmacokinetic parameters of azacitidine; total clearance (CL)

    The total clearance is calculated as Dose/AUC∞

    Time frame: Up to 28 days

  22. Pharmacokinetic parameters of azacitidine; volume of distribution (Vz)

    The volume of distribution will be calculated according to the equation: Vz = (CL)/λz

    Time frame: Up to 28 days

07

Study locations

39 sites
  • St. Anna Kinderkrebsforschung, CHILDREN'S CANCER RESEARCH INSTITUTE
    Vienna, 1090, Austria
  • Hopital Universitaire des Enfants
    Brussels, 1020, Belgium
  • University Hospital Ghent
    Ghent, 9000, Belgium
  • University Hospital Motol
    Prague 5, 150 06, Czechia
  • Rigshospitalet
    Copenhagen, DK-2100, Denmark
  • Centre Hospitalier Universitaire Lyon
    Lyon, 69008, France
  • Hopital d'Enfants de la Timone
    Marseille Cedex 01, 13005, France
  • Hopital Robert Debre
    Paris, 75935, France
  • Klinikum Augsburg
    Augsburg, 86156, Germany
  • Charite Berlin
    Berlin, 13353, Germany
  • Universitaetsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Hematology, Oncology and clinical immunology / Heinrich-Heine-University
    Dusseldorf, 40225, Germany
  • Universitatsklinikum Essen
    Essen, 45147, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main
    Frankfurt am Main, 60596, Germany
  • Universitatsklinik
    Freiburg, 79106, Germany
  • University of Hamburg
    Hamburg, 20246, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitatsklinikum
    Jena, 7740, Germany
  • Universitatsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Klinikum der Universitaet Muenchen
    Munchen, 80336, Germany
  • Universitatsklinik Munster
    Münster, 48149, Germany
  • Krankenhaus Barmherzige Bruder Regensburg
    Regensburg, 93049, Germany
  • Universitatsklinikum
    Tübingen, 72076, Germany
  • Our Lady's Hospital for Sick Children
    Dublin 12, Ireland
  • Policlinico Sant'Orsola-Malpighi
    Bologna, 40138, Italy
  • IRCCS Gaslini Hospital
    Genova Quarto, 16148, Italy
  • Azienda Ospedaliera San Gerardo
    Monza, 20900, Italy
  • General Hospital
    Padova, 35128, Italy
  • IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Ospedale Bambin Gesu
    Roma, 00165, Italy
  • Regina Margherita Children's Hospital
    Torino, 10126, Italy
  • Erasmus University Medical Center
    Rotterdam, 3015 GJ, Netherlands
  • Hospital Sant Joan de Deu
    Barcelona, 8950, Spain
  • Hospital Infantil Universitario Nino Jesus
    Madrid, 28009, Spain
  • Hospital Universitario Virgen de La Arrixaca
    Murcia, 30120, Spain
  • Queen Silvia Childrens Hospital
    Gothenburg, SE-416 85, Sweden
  • Karolinska University Hospital
    Stockholm, SE-171 76, Sweden
  • Universitäts-Kinderklinik
    Zurich, 8032, Switzerland
  • Royal Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
08

References and documents

Publications

  • Niemeyer CM, Flotho C, Lipka DB, Stary J, Rossig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schonung M, Baumann I, Nollke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. doi: 10.1182/bloodadvances.2020004144. PubMed 34297046 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Feb 2018, 29 months.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 29 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2015
First posted
May 19, 2015
StartActual
Sep 15, 2015
Primary completionActual
Feb 28, 2018
CompletionActual
May 24, 2019
Last update
Jul 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02447666
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
May 19, 2015
Start date
Sep 15, 2015
Primary completion
Feb 28, 2018
Completion
May 24, 2019
Last update
Jul 11, 2019

Study contacts

Bouchra Benettaib, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion